Free Trial

Inspirion Wealth Advisors LLC Sells 270,862 Shares of PDS Biotechnology Co. (NASDAQ:PDSB)

PDS Biotechnology logo with Medical background

Inspirion Wealth Advisors LLC decreased its holdings in shares of PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) by 78.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 73,532 shares of the company's stock after selling 270,862 shares during the quarter. Inspirion Wealth Advisors LLC owned about 0.20% of PDS Biotechnology worth $124,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in PDSB. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of PDS Biotechnology during the second quarter valued at about $115,000. Squarepoint Ops LLC bought a new stake in shares of PDS Biotechnology in the 2nd quarter worth approximately $120,000. Cubist Systematic Strategies LLC acquired a new stake in shares of PDS Biotechnology during the 2nd quarter worth approximately $146,000. Vontobel Holding Ltd. increased its position in shares of PDS Biotechnology by 233.3% during the third quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company's stock valued at $153,000 after purchasing an additional 28,000 shares during the period. Finally, XTX Topco Ltd raised its stake in shares of PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company's stock valued at $257,000 after purchasing an additional 47,528 shares in the last quarter. 26.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on PDSB shares. StockNews.com downgraded shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research note on Saturday, November 9th. B. Riley lowered their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a "buy" rating on the stock in a research note on Monday, November 25th. Finally, HC Wainwright restated a "buy" rating and set a $21.00 price target on shares of PDS Biotechnology in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $11.67.

Get Our Latest Research Report on PDSB

PDS Biotechnology Price Performance

Shares of NASDAQ:PDSB traded up $0.02 on Friday, hitting $1.45. The stock had a trading volume of 120,353 shares, compared to its average volume of 246,750. The firm's 50 day moving average price is $1.96 and its 200-day moving average price is $2.86. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. PDS Biotechnology Co. has a twelve month low of $1.30 and a twelve month high of $6.68. The company has a market capitalization of $54.24 million, a price-to-earnings ratio of -1.25 and a beta of 1.90.

About PDS Biotechnology

(Free Report)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.

See Also

Institutional Ownership by Quarter for PDS Biotechnology (NASDAQ:PDSB)

Should You Invest $1,000 in PDS Biotechnology Right Now?

Before you consider PDS Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PDS Biotechnology wasn't on the list.

While PDS Biotechnology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines